Analysts think RARE stock price could increase by 141%
Jun 08, 2025, 11:25 AM
6.62%
What does RARE do
Ultragenyx Pharmaceutical, based in Novato, California, focuses on developing therapies for rare genetic diseases and has four approved products, including Crysvita and Mepsevii. The company went public on January 31, 2014, and employs 1,276 people.
20 analysts think RARE stock price will increase by 141.49%. The current median analyst target is $89.76 compared to a current stock price of $37.17. The lowest analysts target is $39.39 and the highest analyst target is $142.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
